ACUITAS THERAPEUTICS
Live / Registered — Registered (as of 15 Sept 2026)
What this means for you
Registered since 15 Sept 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97915885
- Registration number
- 8429177
- Mark type
- Stylized text
- Filed
- 01 May 2023
- Published for opposition
- 21 Jul 2026
- Registered
- 15 Sept 2026
- Attorney of record
- Karen Won
Goods and services
- Class 001 — Chemicals: Nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders
- Class 042 — Scientific and technological services: Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, and nucleic acid therapeutics as pharmaceutical preparations; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders and allergies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid formulations for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles.
- Class 045 — Legal and security services: Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids in the nature of lipid derivatives for use in the manufacture of pharmaceuticals, vaccines, and drug delivery agents, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics, nucleic acid therapeutics as pharmaceutical preparations, and synthetic chemistry process technology for designing and synthesizing lipid nanoparticles
Owner
- Acuitas Therapeutics, Inc., Vancouver, B.C., CA
- Acuitas Therapeutics, Inc., Vancouver, B.C., CA
- Acuitas Therapeutics, Inc., Vancouver, B.C., CA
Prosecution history
- 15 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 08 Sept 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 21 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jul 2026 — PUBLISHED FOR OPPOSITION
- 15 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 16 Jun 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Jun 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Jun 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Jun 2026 — NON-FINAL ACTION E-MAILED
- 12 Jun 2026 — NON-FINAL ACTION WRITTEN
- 15 May 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 May 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE